ABO21009 / AbolerIS Pharma - LARVOL DELTA

AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis (PRNewswire) - "AbolerIS Pharma...announced today that the first cohort of participants has been dosed with ABO21009, a humanized anti-CD45RC monoclonal antibody, in a first-in-human Phase 1 study for the treatment of Rheumatoid Arthritis (RA)....In part I, 24 patients are planned to be enrolled who will receive one of four single doses of ABO21009 and will be followed up for up to 10 weeks; the Phase 1 study has been initiated in the Netherlands, and is currently enrolling and dosing participants."

Trial status • Rheumatoid Arthritis